FDA Generic Drug User Fee Rates: Fiscal Year 2016

August 7, 2015

As required by the Generic Drug User Fee Amendments of 2012, FDA has announced the 2016 rates for the following user fees:

  • Abbreviated new drug application (ANDA),
  • Prior approval to an ANDA (PAS),
  • Type II active pharmaceutical ingredient drug master file (DMF),
  • Generic drug active pharmaceutical ingredient (API) facilities, and
  • Finished dosage form (FDF) facilities.

These fees are collected to ensure FDA has the needed funds to employ the staff needed to review drugs in a timely manner, thus getting drugs approved and to market in a more efficient time frame. The rates are amended annually and are effective each fiscal year, from October 1 to September 30.

The generic drug user fee rates for fiscal year 2016 are as follows:

Applications:

Fee Category

Fee Rates for FY 2016

Abbreviated New Drug Application (ANDA)

$76, 030

Prior Approval Supplement (PAS) to ANDA

$38,020

Drug Master File (DMF)

$42,170

 

Facilities:

Fee Category

Fee Rates for FY 2016

Active Pharmaceutical Ingredient (API) - Domestic

$40,867

API – Foreign

$55,867

Finished Dosage Form (FDF) – Domestic

$243,905

FDF – Foreign

$258,905

 

Need help deciding which application is right for your generic product? We can help you get through FDA successfully in a more time and cost efficient manner. To learn more about how we can help, please contact us

TAGS:

August 4, 2016

FDA Generic Drug User Fee Rates: Fiscal Year 2017

FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes: Abbreviated new drug applications (ANDAs) Prior approval supplements (PASs) to an approved ANDA...

August 7, 2018

FDA Generic Drug User Fee Rates: Fiscal Year 2019

On Friday, July 27th, FDA released a notice with updated generic drug user fee rates for fiscal year 2019. Under GDUFA II, user fees should total $493,600,000 each year, adjusted for inflation. The...

August 2, 2016

FDA Prescription Drug User Fee Rates: Fiscal Year 2017

The Prescription Drug User Fee Amendments of 2012 (PDUFA V) allows FDA to collect user fees for the review of applications concerning human drug and biological products, the establishments where...